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A B S T R A C T
Background: The increasing number of Novel Psychoactive Substances (NPS) constitutes a challenge for
public health agencies and researchers worldwide. Scientiﬁc studies about NPS and their users are
limited and there is a need to explore the general motivations for NPS use but also to examine if and how
the motivations differ between substances from separate effect classes. The aim of the present study was
to investigate the characteristics, including attitudes and motivations, of a self-selected sample of
international NPS users.
Methods: An online survey containing questions about drug use history, attitudes, motivations for use,
and WHO-5 Wellbeing Index was promoted at the drug discussion forum bluelight.org. The data was
analysed using SPSS.
Results: The sample consisted of 619 international NPS users with overall good emotional well-being
despite extensive experience of both traditional and novel drugs. The main incentive for use of NPS in
general was pleasure and enjoyment. However, going beyond the general approach to NPS revealed
signiﬁcant variations between drug groups. For example, the use of hallucinogens was substantially
motivated by self-exploration and spiritual attainment and showed very low levels of addiction potential
while the use of opioids and especially GABA activating substances was mainly motivated by coping and
showed much higher levels of addiction potential. Synthetic cannabinoids were the least appreciated
and least likely to be used again, and were mainly motivated by circumstances such as availability and
legality.
Conclusion: Understanding the different motivations for NPS use in terms of drug groups could enable
more effective prevention and consequently a reduction in harm.
 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The umbrella term Novel Psychoactive Substances (NPS) refers
to a multitude of progressively increasing compounds that are
marketed as legally ambiguous alternatives to traditional drugs
such as amphetamine, heroin, LSD and cannabis. In 2014, the
European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA, 2015) identiﬁed 101 novel substances in Europe, which
brought the total number of monitored NPS to a staggering
450. Clandestine vendors continuously adapt to regulatory actions
by introducing abandoned medical research chemicals or yet new
and molecularly altered NPS with mostly undocumented and
erratic effects (EMCDDA, 2015; Johnson, Johnson, & Portier, 2013).
Further attempts to evade legal controls include the use of Internet* Corresponding author. Tel.: +46 547002285.
E-mail address: Christophe.Soussan@kau.se (C. Soussan).
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4.0/).as an arena for the open sale of NPS that are often surreptitiously
labeled ‘‘bath salt’’, ‘‘plant food’’, or ‘‘not for human consumption’’
(Gibbons, 2012). Besides the apparent harm potential, the speed at
which this cat and mouse game advances constitutes a challenge
for public health agencies and researchers worldwide (EMCDDA,
2015). Primary literature about side-effects, addiction potential,
toxicological risks, or possible contraindications regarding the
increasing number of NPS is limited (Gibbons, 2012; Wood &
Dargan, 2012). Also, knowledge pertaining to the use of NPS and its
community of users is scarce or contradictory. The prevalence-of-
use rates are uncertain since scientiﬁc studies are limited and
based on different populations or substances. A Eurobarometer
(2014) survey showed that, on average, 8% of youth in Europe
had experience of NPS, which differed considerably from the
65.8% among a targeted population of nightclub visitors in the
UK (Wood, Hunter, Measham, & Dargan, 2012). The typical NPS
user has primarily been depicted as a young male (Vardakou,
Pistos, & Spiliopoulou, 2010; Werse & Morgenstern, 2012)e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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(Barratt, Cakic, & Lenton, 2013). Some NPS users are also known
to be well-informed, knowledgeable, and experienced with drugs
in general (Davey, Schifano, Corazza, & Deluca, 2012; Soussan &
Kjellgren, 2014; Werse & Morgenstern, 2012).
Little knowledge exists about the motivations for NPS use and
additional research is needed to further explore these reasons
(Moore, Dargan, Wood, & Measham, 2013). The vast array of
different NPS presumably entails several intentions for using them.
Some sources have emphasized that the motivation for using NPS
revolves around external circumstances such as price, legal status,
availability or non-detectability in screening tests. Other ﬁndings
suggest that users are driven mainly by curiosity, the enjoyable
effects, or enhancement of social situations (Corazza, Simonato,
Corkery, Trincas, & Shifano, 2014; Measham, Moore, Newcombe, &
Welch, 2010; Werse & Morgenstern, 2012; Winstock, Lawn,
Deluca, & Borschmann, 2015). It is also likely that the motivations
for using NPS overlap with the motivations for using traditional
drugs. A review of the literature on motivations for drug use
exposed several other recurring incentives such as pleasure,
enhancement, coping, self-assertion, habit and addiction, and self-
exploration (e.g. Boys, Marsden, & Strang, 2001; Nicholson,
Duncan, & White, 2002; Novacek, Raskin, & Hogan, 1991). Many
of these motives have appeared inductively in our previous
research about different NPS. For example, the use of the novel
stimulant ethylphenidate was characterized by salient addiction
potential and sought-after effects such as self-conﬁdence, social
facilitation and cognitive enhancement (Soussan & Kjellgren,
2015). In addition, our investigation into the experiences induced
by the novel hallucinogen 4-HO-MET showed that the main reason
for use was curiosity and self-exploration while experiences of
addiction were absent (Kjellgren & Soussan, 2011). This supports
the notion that traditional drug use motives to some extent applies
to NPS as well, but it also indicates that the motivations for NPS use
might vary between substances from different effect-classes, as in
the case of the hallucinogen and the stimulant described above.
The assumption of NPS speciﬁc motivations is further substantiat-
ed by the fact that legality constituted a major incentive for the
use of synthetic cannabinoids (Werse & Morgenstern, 2012) while
the appeal of the novel stimulant mephedrone was found to
be uninﬂuenced by legal status (Moore et al., 2013). Hence,
approaching the motivations from a broad and all-encompassing
perspective of NPS in general will occasionally be unreﬁned,
especially considering that a more nuanced understanding of the
different pathways to drug use is assumed to be essential in
enabling effective treatment, prevention and consequently a
reduction in harm (Adams et al., 2003). Therefore it is important
not only to study the motivations for NPS use in general but also
to examine more fully if and how the motivational characteristics
of each group of NPS differentiate.
The aim of the present study was to investigate the
characteristics, including attitudes and motivations, of a self-
selected sample of international NPS users.
Methods
Data collection
The data were collected through an online survey, which was
promoted at the international drug discussion forum bluelight.org.
The survey consisted of three parts. The ﬁrst part concerned
background data including age, gender, country of residence,
traditional drug use history, and number of different NPS used
within the last ﬁve years.
The second part of the survey contained a set of NPS speciﬁc
questions including substance name, way of acquisition, and11 visual analogue scale (VAS) items with end points 0 (‘‘Not at
all’’) to 100 (‘‘Highly appreciated/motivated’’), etc. The ﬁrst three
items investigated the extent to which the participants (1)
appreciated the effects, (2) planned on using the substance again,
and (3) estimated the addictive potential. The next eight VAS items
concerned the motivation for using the speciﬁed NPS. The
participants were asked to evaluate the extent to which they
were motivated by (1) pleasure and enjoyment, (2) facilitation of
social situations, (3) enhanced mental or physical abilities, (4) coping
with pain, boredom, emotions and problems like anxiety and sleep
deprivation, (5) self-assertion or self-conﬁdence, (6) habit or
addiction, (7) self-exploration or spiritual attainment, and (8)
circumstances such as price, legal status, availability or non-
detectability in screening tests. The eight motives were abstracted
from the literature on motivations for drug use (see Background
section). The NPS speciﬁc set of questions was repeated for (and
limited to) each of every participant’s three most recent and
distinct NPS experiences. The survey software ensured that the
initially stated number of used NPS determined the number of
repetitions, meaning that every participant reported between
one and three cases of NPS use. This part of the survey also included
an open-ended question regarding the reasons for using NPS that
will be analysed and published elsewhere.
In the third part of the survey the respondents were asked to
ﬁll out the World Health Organization (WHO) Wellbeing Index
(WHO-5), which is a well validated ﬁve-item questionnaire for
assessing the subjective and psychological well-being (Topp,
Østergaard, & Søndergaard, 2015). The well-being index ranges
from 0, ‘‘complete absence of well-being’’, to 100, ‘‘the highest
imaginable level of well-being’’. A score of 50 or lower suggests
poor emotional well-being.
The survey was online between November 2014 and February
2015 and yielded 1551 cases of NPS use reported by 619 partici-
pants. No questions were left unanswered since all ﬁelds were
compulsory. Uncompleted survey attempts were removed auto-
matically by the survey software.
Analysis
Each case of NPS use was categorized according to one of the
following effect classes: hallucinogen, stimulant, dissociative,
GABA activating drugs (henceforth GABA), synthetic cannabinoid,
opioid and other-than-NPS. We categorized the following as other-
than-NPS: (1) cases involving a combination of drugs, or (2) cases
based on one of the following substances: alcohol, nicotine,
cannabis, cocaine, LSD, amphetamine, heroin, psilocybin, and
mescaline. According to Corazza, Demetrovics, van den Brink, and
Schifano (2013), ‘‘novel’’ does not necessarily mean new but also
incorporates long-existing substances ‘‘which have recently
become popular in the drug market’’. Therefore, a few grey-zone
cases were categorized as novel if they were frequently reported.
Next, the data were analyzed using common statistical
procedures in SPSS (descriptives and frequencies). A one-way-
ANOVA was used to analyze if the motivation for using NPS was
signiﬁcantly different between drug groups.
Ethical considerations
The participants were informed about the study and its purpose
before participating. They were also informed that participation
was completely voluntary, and that they could withdraw from the
study at any time without specifying why, as long as the survey
was uncompleted. In addition, participation was anonymous and
no questions about identity were asked. In order to participate
the users had to verify being 18 years or older and that their latest
use of NPS took place less than two years ago. The collected data
Table 1
The frequency distribution for each substance group among the 1551 cases.
Substance group Number of cases Percent
Hallucinogens 629 40.5
Stimulants 355 22.9
Dissociatives 156 10.1
GABA 106 6.9
Synthetic cannabinoids 90 5.9
Opioids 53 3.3
NPS total 1388 89.5
Other than NPS 163 11.8
Total 1551 100.0
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privacy so no unauthorized people can access it. The study was
ethically approved by Karlstad University Ethical Review Board,
dnr C2014/419.
Results
The sample
A total of 619 persons (517 males, 102 females) completed
the survey. Their mean age was 27.6 years (SD = 9.47,
median = 25 years) and the range was 18–75 years. The mode
age was 18 years for both genders. There was a signiﬁcant
difference in age between males and females (independent
samples t-test, t(618) = 2.66, p = 0.008), where the males were
slightly younger (mean = 27.1, SD = 9.30) than the females
(mean = 29.8, SD = 10.0). The sample consisted of respondents
from 42 different countries, and the ten most frequently occurring
countries were: USA (48.9%), United Kingdom (14.2%), Canada
(7.3%), Sweden (5.5%), Holland (3.7%), Australia (3.4%), Germany
(2.9%), Finland (1.0%), France (1.0%), and Poland (1.0%). The WHO-5
Well-being questionnaire had high reliability (Cronbach’s a = .86),
and the mean index for all respondents was 57.9 (SD = 20.2). The
mean consumption of pure alcohol in an average month (wine,
beer and spirits) was 504 ml (SD = 900). The sample contained
322 cigarette users (52%) for whom the mean consumption during
an average month was 170 cigarettes (SD = 219).
Traditional drug use
Lifetime experience of at least one illicit and traditional drug
was 99%. More speciﬁcally, 98.2% of the respondents had taken
cannabis, 84.5% a hallucinogen (LSD or psilocybin), 80% a stimulant
(amphetamine or cocaine), and 42.3% an opiate (heroin or
morphine). Past year use of cannabis was reported by 88% of
the respondents, and they had used it on average 239 times
(SD = 392) during the period. The equivalent numbers for
hallucinogens was 61% prevalence (mean = 7.5 times, SD = 14.6),
while past year use of stimulants was reported by 57%
(mean = 45.1 times, SD = 110). Opiate use was less common but
more frequently used (prevalence = 27.3%, mean = 82.5, SD = 173).Table 2
The 20 most frequently used substances among the 1551 cases of NPS and the average e
same substance again, and (3) estimated the addictive potential.
NPS Number of cases Drug group 
Methoxetamine 110 Dissociative 
25i-NBOMe 66 Hallucinogen 
4-AcO-DMT 65 Hallucinogen 
2C-B 60 Hallucinogen 
Etizolam 55 GABA 
Al-LAD 53 Hallucinogen 
4-HO-DET 44 Hallucinogen 
Ethylphenidate 44 Stimulant 
Kratom 30 Opioid 
Methylone 29 Stimulant 
MDMA 29 Stimulant 
4-Fluoroamphetamine 28 Stimulant 
Mephedrone 27 Stimulant 
5-MeO-MiPT 25 Hallucinogen 
AMT 25 Stimulant 
25c-NBOMe 24 Hallucinogen 
2C-E 23 Hallucinogen 
Salvia divinorum 21 Hallucinogen 
3-MeO-PCP 19 Dissociative 
Dextromethorphan 19 Dissociative NPS use
The number of different NPS experienced by each respondent
during the last ﬁve years varied; 29.6% had used nine or more NPS,
16% two NPS, 15% one NPS, 11.8% three NPS, 8.7% ﬁve NPS, 7.6%
four NPS, 5.8% six NPS, 2.9% seven NPS, and 2.6% eight NPS. The
three most recent NPS exposures for every respondent were
queried speciﬁcally and in more detail (see Methods section).
The total number of drug cases reported by the 619 respondents
amounted to 1551, of which 409 (66.2%) reported three cases, 112
(18.1%) two cases and 98 (15.8%) one case. Respondents with
experience of more than one NPS (n = 521) were inclined to use
substances from different drug groups; only 24% reported all cases
within the same group.
The most frequently occurring substance groups were hallu-
cinogens (40.5%), stimulants (22.9%), and dissociatives (10.1%)
(Table 1). In total, the use of 177 different NPS was reported.
The three most common NPS were methoxetamine (110 cases),
25i-NBOMe (66 cases), and 4-AcO-DMT (65 cases) (Table 2).
The most common way of acquiring NPS was through the
Internet (60.4%), while other means were friends (17.8%), dealer
(9.5%), physical shop (5.1%), free sample (2.7%), other such as
‘‘rather not say’’ (2.6%), and self-made (1.9%).
Attitudes and motivation for using NPS
The primary motivation for using NPS in general, regardless of
drug group, was pleasure and enjoyment (mean = 70.8, SD = 29.2).xtent to which the respondents (1) appreciated the effects, (2) planned on using the
Appreciation Plan on reuse Addictiveness
81.8 72.4 55.9
66.9 33.9 9.5
81.7 77.2 5.6
75.2 65.7 13.4
77.7 75.7 74.7
87.6 85.9 4.6
81.7 72.9 7.7
56.6 59.3 55.98
70.8 74.3 52.0
65.5 49.1 49.3
86.9 80.1 37.8
73.4 71.3 45.2
78.8 52.8 69.8
71.5 63.7 19.4
82.8 63.0 13.6
62.2 39.0 14.6
78.9 72.1 9.8
51.0 50.1 3.7
83.1 69.3 43.7
75.2 60.7 40.8
Table 3
The mean approval rates for each motivation split by drug group.
Motivated by Hallucinogens Stimulants Dissociatives GABA Synthetic
cannabinoids
Opioids Total
Pleasure and enjoyment? 68.9 (SD = 29.6) 72.9 (SD = 29.0) 77.0 (SD = 23.0) 60.8 (SD = 33.5) 70.4 (SD = 29.9) 80.6 (SD = 25.3) 70.8 (SD = 29.2)
Facilitation of social situations? 22.9 (SD = 28.6) 43.1 (SD = 35.5) 26.4 (SD = 29.3) 45.7 (SD = 36.8) 28.8 (SD = 31.2) 25.5 (SD = 29.6) 30.7 (SD = 32.7)
Enhanced mental or physical abilities? 45.5 (SD = 36.4) 56.5 (SD = 34.9) 38.0 (SD = 35.1) 28.8 (SD = 33.4) 18.5 (SD = 27.6) 35.6 (SD = 33.6) 44.0 (SD = 36.5)
Coping with pain, boredom, emotions,
problems, anxiety, sleep deprivation?
24.7 (SD = 29.7) 35.5 (SD = 34.6) 49.7 (SD = 33.9) 77.2 (SD = 26.9) 47.5 (SD = 37.4) 68.9 (SD = 30.6) 37.4 (SD = 35.6)
Self-assertion and self-conﬁdence? 21.7 (SD = 28.8) 36.0 (SD = 32.5) 27.4 (SD = 30.7) 35.3 (SD = 36.1) 15.6 (SD = 23.8) 22.2 (SD = 28.2) 26.7 (SD = 31.0)
Habit or addiction? 8.3 (SD = 15.9) 25.6 (SD = 32.0) 25.6 (SD = 28.7) 31.9 (SD = 33.6) 25.2 (SD = 30.4) 51.4 (SD = 38.1) 19.2 (SD = 28.1)
Self-exploration or spiritual attainment? 76.6 (SD = 29.3) 33.1 (SD = 33.9) 68.3 (SD = 30.6) 17.4 (SD = 25.5) 28.4 (SD = 30.8) 28.6 (SD = 33.2) 55.1 (SD = 38.4)
Circumstances such as price, legal status,
availability, non-detectability
in screening tests?
40.6 (SD = 37.0) 48.4 (SD = 37.8) 51.6 (SD = 35.6) 64.0 (SD = 34.2) 66.3 (SD = 36.9) 55.7 (SD = 36) 47.9 (SD =37.7)
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across all NPS was 70.8 (SD = 28.8), and the extent to which the
respondents planned on using the substance again was 60.7
(SD = 38.4). The addictive potential of all the reported NPS was
estimated at 32.6 (SD = 33.1). However, both the motivations and
the attitudes varied signiﬁcantly between drug groups. The means
and standard deviations are presented in Table 3 and illustrated
in Fig. 2a–f. The variations in attitudes are illustrated in Fig. 1. The
most signiﬁcant mean differences (abbreviated MD below)
between drug groups and their speciﬁc characteristics are outlined
below. The most common NPS in each group was deﬁned by a
threshold of 50% saturation or the three most frequent substances.
Hallucinogens
The most common NPS in this group were 25i-NBOMe (10.5%),
4-AcO-DMT (10.3%), 2C-B (9.5%), AL-LAD (8.4%), 4-HO-DET (7.0%),
and 5-MeO-MiPT (4.0%). The most approved motivation for
hallucinogens was self-exploration or spiritual attainment
(mean = 76.6, SD = 29.4) (Fig. 2a), which was signiﬁcantly
(ps < 0.001) higher than all other groups; GABA (MD = 59.1),
synthetic cannabinoids (MD = 48.1), opioids (MD = 47.97), stimu-
lants (MD = 43.4), and dissociatives (p = 0.038, MD = 8.3). Halluci-
nogens also stood out among all other groups in that they had
signiﬁcantly (ps < 0.001) lower scores on habit and addiction
(mean = 8.31, SD = 15.9) compared with all other groups. See
Table 3 for comparison of means. In addition, the respondents
considered the hallucinogenic NPS to have signiﬁcantlyFig. 1. The extent to which the respondents (1) appreciated the effects, (2) planned on usi
group.(ps < 0.001) less addictive potential (mean = 8.8, SD = 13.4) than
all other groups (Fig. 1).
Stimulants
The most common NPS in this group were ethylphenidate
(12.4%), methylone (8.2%), MDMA (8.2%), 4-ﬂuoroamphetamine
(7.9%), mephedrone (7.6%), and 5-MAPB (4.8%). According to the
respondents, the primary motivation for using stimulants was
pleasure and enjoyment (mean = 72.9, SD = 28.9) (Fig. 2b). However,
enhancement of mental and physical abilities (mean = 56.5,
SD = 34.9) distinguished stimulants (ps < 0.001) from synthetic
cannabinoids (MD = 38.0), GABA (MD = 27.7), opioids (MD = 20.9),
dissociatives (MD = 18.5), and hallucinogens (MD = 10.9). Further-
more, stimulants had signiﬁcantly (p = 0.002) higher scores on
facilitation of social situations (mean = 43.1, SD = 35.5) than all other
drug groups except for GABA. See Table 3 for comparison of means.
Dissociatives
The most common NPS in this group were methoxetamine
(70.5%), 3-MeO-PCP (12.2%), and dextromethorphan (12.2%). The
highest ranked motivation was pleasure and enjoyment
(mean = 77.0, SD = 23.0) (Fig. 2c). The use of dissociatives for
self-explorative or spiritual purposes (mean = 68.3, SD = 30.7) had
signiﬁcantly (ps < 0.001) higher prevalence compared with the
following drug groups: GABA (MD = 50.8), synthetic cannabinoids
(MD = 39.8), opioids (MD = 39.7), and stimulants (MD = 35.1). The
dissociatives were also characterized by having the highest scoreng the same substance again, and (3) estimated the addictive potential. Split by drug
0.00
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20.0 0
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40.0 0
50.0 0
60.0 0
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Fig. 2. (a) The mean motivation proﬁle for hallucinogens. (b) The mean motivation proﬁle for stimulants. (c) The mean motivation proﬁle for dissociatives. (d) The mean
motivation proﬁle for GABA. (e) The mean motivation proﬁle for synthetic cannabinoids. (f) The mean motivation proﬁle for opioids.
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(mean = 70.3, SD = 35.0) of all the drug groups.
GABA
The most common NPS in this group was etizolam (51.9%),
ﬂubromazepam (11.3%), and diclazepam (7.5%). Use of GABA wasprimarily driven by coping with life challenges (mean = 77.2,
SD = 26.9) (Fig. 2d), which was signiﬁcantly (ps < 0.001) different
from hallucinogens (MD = 52.5), stimulants (MD = 41.7), synthetic
cannabinoids (MD = 29.6), and dissociatives (MD = 27.5). In addi-
tion, GABA signiﬁcantly (ps < 0.03) differed from all other groups
except stimulants in that they to a larger extent were used for
0.00
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40.0 0
50.0 0
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70.0 0
80.0 0
90.0 0
Synthetic Cannabinoids f e
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Fig. 2. (Continued ).
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comparison of means. This group was also characterized by
having the lowest pleasure and enjoyment mean (60.8, SD = 33.5)
of all groups. GABA was also estimated to have the highest
addictive potential (mean = 70.6, SD = 28.8) of all groups.
Synthetic cannabinoids
The most common NPS in this group were unspeciﬁed
cannabinoid (25.6%), followed by branded cannabinoid with
unknown psychoactive substance (20.0%), and the cannabinoid
JWH-018 (8.9%). The primary motivation for using synthetic
cannabinoids was pleasure and enjoyment (mean = 70.4,
SD = 29.9), followed by circumstances such as price, legal status,
availability, non-detectability in screening tests (mean = 66.3,
SD = 36.9) (Fig. 2e). The extent to which these circumstances
acted as motivation was signiﬁcantly greater than for hallucino-
gens (p < 0.001, MD = 25.7), stimulants (p = 0.001, MD = 17.9), and
dissociatives (p < 0.038, MD = 14.7). In general, synthetic canna-
binoids had lower scores across all motivations (Table 3). They also
had signiﬁcantly (ps < 0.001) lower scores on both appreciation of
effects (MD1) (mean = 44.8, SD = 30.3) and plan on re-use (MD2)
(mean = 27.2, SD = 35.5) compared with all other groups; dis-
sociatives (MD1 = 35.2, MD2 = 43.1), hallucinogens (MD1 = 29.4,
MD2 = 36.7), GABA (MD1 = 26.6 MD2 = 41.6), opioids (MD1 = 25.98,
MD2 = 40.7), and stimulants (MD1 = 22.2, MD2 = 28.5). See Fig. 1 for
an illustrative comparison.
Opioids
The most common NPS in this group were Kratom (56.6%), AH-
7921 (9.4%) and o-desmethyltramadol (5.7%). The highest approval
rates were given to pleasure and enjoyment (mean = 80.6,
SD = 25.3) (Fig. 2f), which also constituted the largest mean across
all drug groups and motivations. Furthermore, opioids were to a
greater extent used for coping with life challenges (mean = 68.9,
SD = 30.6) compared with all other groups except for GABA;hallucinogens (p < 0.001, MD = 44.2), stimulants (p < 0.001,
MD = 33.4), synthetic cannabinoids (p = 0.002, MD = 21.4), and
dissociatives (p = 0.002, MD = 19.2). Also, the use of opioids was
signiﬁcantly (ps < 0.001) more motivated by habit and addiction
(mean = 51.4, SD = 38.0) compared with all other drug groups. See
Table 3 for comparison of means. The addictive potential of opioids
was also considered to be signiﬁcantly (ps < 0.001) larger than for
all other groups except GABA: hallucinogens (MD = 55.8), synthetic
cannabinoids (MD = 27.0), stimulants (MD = 16.1), and dissocia-
tives (p = 0.015, MD = 12.7).
Discussion
The purpose of the present study was to investigate the
characteristics, including attitudes and motivations, of a self-
selected sample of international NPS users. The results exposed
several distinct and drug group related motivation proﬁles, which
were based on a sample of 619 experienced drug users with an
afﬁnity for both traditional and novel substances, indicating that
the two go hand in hand. Lifetime experience of traditional drugs
was 99% and the majority of the participants (85%) had used
several NPS during the last ﬁve years. Perhaps even more
remarkable is that close to 30% of the participants had experience
of nine or more NPS, which was nearly twice as many as those with
experience of one NPS (15%). Moreover, a comprehensive total of
177 different NPS had been used among the 619 participants,
reﬂecting a drive towards varied and novel drug experiences that
was further supported by the fact that three quarters (76%) of the
participants with multiple NPS experiences had used substances
belonging to different drug groups. The numbers stated in
parenthesis throughout the discussion are rounded off to the
nearest integer and if nothing else is stated the numbers refer to
the mean VAS-scale scores from 0 to 100.
The majority of participants were young males (mode 18 years),
which is consistent with previous ﬁndings (Vardakou et al., 2010;
C. Soussan, A. Kjellgren / International Journal of Drug Policy 32 (2016) 77–84 83Werse & Morgenstern, 2012). However, a broad range of ages up to
75 years (mean 28 years) of both genders (16% females and 84%
males) was represented, indicating that the use of NPS is not
exclusively a youth male phenomenon. The females were slightly
but signiﬁcantly older than the males. Despite extensive drug
experience, the participants appeared to have good quality of life,
indicated by the sample’s overall well-being score of 58, which
according to Topp et al. (2015) is above the suggested threshold
(50) for poor well-being. Interestingly enough, the mean con-
sumption of alcohol per participant and year (6 l) was marginally
less than the average worldwide consumption (6.2 l) (WHO, 2014),
which means that the sample did not use alcohol in excess of the
general population.
Although the Internet is usually purported as the main arena in
which NPS are marketed and sold, it turned out that close to 40% of
the NPS reported in this study were acquired through other means,
mainly friends and dealers. Similarly, another study (Sande, 2016)
showed that the majority of a sample of novel stimulant users in
Slovenia obtained their drugs from friends or dealers as opposed to
the Internet. This shift towards a greater reliance on real world
interactions is known to occur when an NPS is banned (McElrath
& O’Neill, 2011), which indicates that a gradual overlapping
between the traditional and novel markets is taking place.
It is noteworthy that the characteristics usually associated with
the use of novel substances in particular, such as being affordable,
legal, available and non-detectable in screening tests, constituted
a signiﬁcantly less endorsed motivation (48) than pleasure and
enjoyment (71) which was the most approved motivation for using
NPS in general. Recent research (Sande, 2016) partly agrees with
the notion that some circumstances, such as the legality of NPS and
lack of access to traditional drugs, are less important reasons for
NPS use while, on the other hand, other circumstances such as low
price and high purity were among the most important reasons.
Nevertheless, several studies of both traditional (Boys et al., 2001;
Novacek et al., 1991) and novel (Corazza et al., 2014; Werse &
Morgenstern, 2012) drugs support our ﬁnding that pleasure, in the
form of ‘‘enjoying intoxication’’ and ‘‘having a good time’’, is the
key incentive for using drugs, but what does that imply? In our
earlier studies (Kjellgren & Soussan, 2011), we have concluded that
recreational NPS users were more concerned with experiencing
per se rather than the desire for speciﬁc experiential content such
as euphoria. This drive towards non-ordinary and novel experi-
ences can explain why the overall effects, positive or negative,
of the reported NPS were appreciated to a large degree (71), and
why the participants for the most part planned on using the NPS
again (61).
Furthermore, the participants estimated that the addictive
potential of NPS in general was comparatively low (33), which can
be viewed as an expression of denial but can also mean that some
types of NPS are experienced as insigniﬁcantly addictive. Going
beyond the broad-brush approach to NPS by analysing the results,
not at the general level but at the level of drug groups, revealed
signiﬁcant variations in motivation and attitudes. For example, the
estimated addictive potential was remarkably lower for hallucino-
gens (9) than for GABA (71) and opioids (65). The variations in
addictiveness were further validated by the participants’ approval
of the different motivations for using NPS, which showed that
habit and addiction constituted only a minor incentive for use of
hallucinogens (8) but much more so for opioids (51) and GABA
(32). In addition, the past year use of traditional drugs revealed a
similar drug group pattern where the use of hallucinogens was
more prevalent but considerably less frequent (8 times) than
stimulants (45 times) and opioids (83 times) (GABA was not
queried). Hence, there are strong reasons to believe that the
prevalence and frequency of use and the addiction potential of NPS
are drug group dependent.Besides variations in addictiveness, the results exposed several
other distinctive characteristics inherent to each drug group.
Synthetic cannabinoids were the least appreciated (45) and the
least likely to be used again (27), most probably reﬂecting their
numerous and quite severe side effects (Soussan & Kjellgren,
2013), and the fact that 93% of a population of synthetic
cannabinoid users essentially preferred traditional cannabis
(Winstock & Barratt, 2013). Also, it was found that the use of
synthetic cannabinoids was to a larger extent than any other drug
group motivated by circumstances such as price, legal status,
availability and non-detectability in screening tests (66), which
further establishes their position as mostly a substitute for users in
need of an alternative to traditional cannabis.
The mean motivations and attitudes clearly show that there is a
speciﬁc proﬁle to each drug group that includes but also goes
beyond the obvious and general pleasure and enjoyment incentive
(Fig. 1 and Figs. 2a to 2f). Hallucinogens were substantially
motivated by self-exploration and spiritual attainment (77). So
were the dissociatives (68) but with the difference that they to
a greater extent were linked to habit and addiction. The use of
opioids (69) and especially GABA (77) was, besides connected with
addiction, mainly motivated by coping with pain, boredom,
emotions, problems, anxiety, and sleep deprivation. GABA, however,
stood out in being more of a social facilitator type of drug (46) than
opioids (26). Stimulants, on the other hand, were also associated
with the facilitation of social situations (43) but were to a greater
extent used to enhance mental and physical abilities (57), which is
in line with previous ﬁndings demonstrating that substances such
as ethylphenidate is increasingly used as ‘‘social lubricants’’ and
cognitive enhancers (Soussan & Kjellgren, 2014).
Although the different drug groups to some extent overlap in
motivation and attitudes, it is our conviction that they attract users
for different reasons such as inner exploration, self-medication,
cognitive enhancement, novel sensation seeking and so forth.
The point here is not only to outline the speciﬁc differences in
motivations but also to show that approaching NPS in terms of
drug groups can reveal crucial information to legislators, preven-
tion strategists and health care personnel, especially considering
that a more nuanced understanding of the different pathways to
drug use is believed to be essential in enabling effective treatment,
prevention and consequently a reduction in harm (Adams et al.,
2003). Hence, identifying not only the general but the speciﬁc
reasons for NPS use will most likely improve the efﬁciency of
interventions aimed at preventing the behavior or reducing its
harm. In addition, more subtle and detailed knowledge about the
motivations and addiction potential of different drug groups can
also be used to allocate resources to areas where harm potential
is the most prevalent more quickly. In essence, understanding the
different pathways to NPS use can enable more effective drug
prevention strategies and consequently a reduction in harm.
Limitations
This study may have been limited by the use of a self-selected
sample of NPS users who previously have been characterized as
well-informed, knowledgeable and connoisseur-like (Davey et al.,
2012; Soussan & Kjellgren, 2014; Werse & Morgenstern, 2012).
Furthermore, gathering data online frustrates any attempt to
conﬁrm the identity of the reported substances. Therefore we do
not claim the results to be representative of a wider population
although the bias towards experienced users could just as well
have contributed to richer and more nuanced responses and the
validity of substance identities than otherwise. The eight VAS
items concerning the motivation for NPS use may have limited the
results as they were abstracted from the conventional literature on
drugs, which means that novel or qualitatively unique motivations
C. Soussan, A. Kjellgren / International Journal of Drug Policy 32 (2016) 77–8484could have been missed. Therefore, further research should make
use of qualitative and inductive methods of analysis in order to
capture potential motivation for NPS use that goes beyond the
preconceived ones.
Acknowledgements
The authors wish to acknowledge the Public Health Agency of
Sweden, which supported the present study with unrestricted
grants. The authors would also like to thank Elisabeth Wenno¨ for
proofreading the manuscript. The authors would also like to
acknowledge the Internet forum bluelight.org for their supportive
attitude towards research.
Conﬂict of interest: The authors declare that they have no conﬂict of
interest.
References
Adams, J. B., Heat, A. J., Young, S. E., Hewitt, J. K., Corley, R. P., & Stallings, M. C. (2003).
Relationships between personality and preferred substance and motivations for
use among adolescent substance abusers. The American Journal of Drug and Alcohol
Abuse, 29, 691–712. http://dx.doi.org/10.1081/ADA-120023465
Barratt, M. J., Cakic, V., & Lenton, S. (2013). Patterns of synthetic cannabinoid use
in Australia. Drug and Alcohol Review, 32, 141–146. http://dx.doi.org/10.1111/j.
1465-3362.2012.00519.x
Boys, A., Marsden, J., & Strang, J. (2001). Understanding reasons for drug use amongst
young people: A functional perspective. Health Education Research, 16, 457–469.
http://dx.doi.org/10.1093/her/16.4.457
Corazza, O., Demetrovics, Z., van den Brink, W., & Schifano, F. (2013). ‘Legal highs’ an
inappropriate term for ‘Novel Psychoactive Drugs’ in drug prevention and scientiﬁc
debate. International Journal of Drug Policy, 24, 82–83. http://dx.doi.org/10.1016/
j.drugpo.2012.06.005
Corazza, O., Simonato, P., Corkery, J., Trincas, G., & Shifano, F. (2014). ’’Legal highs’’: Safe
and legal ‘‘heavens’’? A study on the diffusion, knowledge and risk awareness
of novel psychoactive drugs among students in the UK. Rivista di Psichiatria, 49,
89–94. http://dx.doi.org/10.1708/1461.16147
Davey, Z., Schifano, F., Corazza, O., & Deluca, P. (2012). e-Psychonauts: Conducting
research in online drug forum communities. Journal of Mental Health, 21, 386–394.
Eurobarometer 401 (2014). Young people and drugs. http://ec.europa.eu/public_
opinion/ﬂash/ﬂ_401_en.pdf Accessed 21.09.15.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015). New
psychoactive substances in Europe. http://www.emcdda.europa.eu/publications/
2015/new-psychoactive-substances Accessed 12.09.15.
Gibbons, S. (2012). ‘Legal highs’ – Novel and emerging psychoactive drugs: a chemical
overview for the toxicologist. Clinical Toxicology, 50, 15–24. http://dx.doi.org/
10.3109/15563650.2011.645952
Johnson, L. A., Johnson, R. L., & Portier, R. (2013). Current ‘‘legal highs’’. The Journal of
Emergency Medicine, 44, 1108–1115. http://dx.doi.org/10.1016/j.jemermed.2012.09.
147Kjellgren, A., & Soussan, C. (2011). Heaven and hell – A phenomenological study of
recreational use of 4 HO-MET in Sweden. Journal of Psychoactive Drugs, 43, 211–
219. http://dx.doi.org/10.1080/02791072.20l1.605699
McElrath, K., & O’Neill, C. (2011). Experiences with mephedrone pre- and post-legislative
controls: Perceptions of safety and sources of supply. International Journal of Drug
Policy, 22, 120–127. http://dx.doi.org/10.1016/j.drugpo.2010.11.001
Measham, F., Moore, K., Newcombe, R., & Welch, Z. (2010). Tweaking, bombing,
dabbing and stockpiling: The emergence of mephedrone and the perversity of
prohibition. Drugs and Alcohol Today, 10, 14–21. http://dx.doi.org/10.5042/daat.
2010.0123
Moore, K., Dargan, P. I., Wood, D. M., & Measham, F. (2013). Do novel psychoactive
substances displace established club drugs, supplement them or act as drugs of
initiation? The relationship between Mephedrone, Ecstasy and Cocaine. European
Addiction Research, 19, 276–282. http://dx.doi.org/10.1159/000346678
Nicholson, T., Duncan, D. F., & White, J. B. (2002). Is recreational drug use normal? Journal
of Substance Use, 7, 116–123. http://dx.doi.org/10.1080/14659890209169340
Novacek, J., Raskin, R., & Hogan, R. (1991). Why do adolescents use drugs? Age, sex, and
user differences. Journal of Youth and Adolescence, 20, 475–492. http://dx.doi.org/
10.1007/BF01540632
Sande, M. (2016). Characteristics of the use of 3-MMC and other new psychoactive
drugs in Slovenia, and the perceived problems experienced by users. International
Journal of Drug Policy, 27, 65–73. http://dx.doi.org/10.1016/j.drugpo.2015.03.005
Soussan, C., & Kjellgren, A. (2013). The ﬂip side of ‘‘spice’’: The adverse effects of
synthetic cannabinoids as discussed on a Swedish Internet forum. Nordic Studies on
Alcohol and Drugs, 31, 1–13. http://dx.doi.org/10.2478/nsad-2014-0016
Soussan, C., & Kjellgren, A. (2014). Harm reduction and knowledge exchange – A
qualitative analysis of drug-related Internet discussion forums. Harm Reduction
Journal, 11 http://dx.doi.org/10.1186/1477-7517-11-25
Soussan, C., & Kjellgren, A. (2015). ’’Chasing the high’’ – Experiences of ethylphenidate
as described on international internet forums. Substance Abuse: Research and
Treatment, 9, 9–16. http://dx.doi.org/10.4137/SART.S22495
Topp, C. W., Østergaard, S. D., & Søndergaard, S. (2015). The WHO-5 well-being index:
A systematic review of the literature. Psychotherapy and Psychosomatics, 84,
167–176. http://dx.doi.org/10.1159/000376585
Vardakou, I., Pistos, C., & Spiliopoulou, C. (2010). Drugs for youth via Internet and the
example of mephedrone. Toxicology Letters, 201, 191–195. http://dx.doi.org/10.
1016/j.toxlet.2010.l2.014
Werse, B., & Morgenstern, C. (2012). How to handle legal highs? Findings from a
German online survey and considerations on drug policy issues. Drug and Alcohol
Today, 12, 222–231. http://dx.doi.org/10.1108/17459261211286636
Winstock, A. R., & Barratt, M. J. (2013). Synthetic cannabis: A comparison of patterns of
use and effect proﬁle with natural cannabis in a large global sample. Drug and
Alcohol Dependence, 131, 106–111. http://dx.doi.org/10.1016/j.drugalcdep.2012.
12.011
Winstock, A. R., Lawn, W., Deluca, P., & Borschmann, R. (2015). Methoxetamine: An
early report on the motivations for use, effect proﬁle and prevalence of use in a UK
clubbing sample. Drug and Alcohol Review. http://dx.doi.org/10.1111/dar.12259
World Health Organization (WHO) (2014). Global status report on alcohol and health –
2014. http://www.who.int/substance_abuse/publications/global_alcohol_report
Accessed 19.09.15.
Wood, D. M., & Dargan, P. I. (2012). Understanding how data triangulation identiﬁes
acute toxicity of novel psychoactive drugs. Journal of Medical Toxicology, 8, 300–
303. http://dx.doi.org/10.1007/s13181-012-0241-3
Wood, D. M., Hunter, L., Measham, F., & Dargan, P. I. (2012). Limited use of novel
psychoactive substances in South London nightclubs. QJM, 105, 959–964. http://
dx.doi.org/10.1093/qjmed/hcs107
